NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Sanofi (SNY) Stock Analysis

Sanofi (SNY) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

SNY

$44.24

−$0.09 (−0.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNY with… →

SNY Key Statistics

As of Sep 4, 2026
Trading
Open
$44.17
Previous Close
$44.33
Day's Range
44.03–44.36
52-Week Range
40.89–52.68
Volume
1.69M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.28
Valuation
Market Cap
$106.01B
P/E Ratio
23.53
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
8.16
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
29.56
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.17
EPS (ttm)Profit attributable to each share over the last twelve months.
1.88
Financials (FY)
Revenue (FY)
$46.72B+5.49%
Net Income (FY)
$7.81B+40.52%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.09%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.40B
1-Year Return
+3.01%
Dividend and dates
Dividend
$2.42+5.46%
Ex-Dividend Date
May 4, 2026
Earnings Date
October 30, 2026
Avg Volume
3.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−3.64%
2025+4.93%
2024+1.09%
2023+6.55%
2022+0.47%
2021+7.00%
2020+0.38%
2019+20.47%
2018+6.06%
2017+9.82%
2016 (partial year)+0.95%

As of September 4, 2026.

SNY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$46.72B$7.81B16.7%
2024$44.29B$5.56B12.6%
2023$41.62B$5.40B13.0%
2022$40.56B$8.37B20.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$46.72B$33.67B$9.60B$7.81B16.7%
2024$44.29B$31.08B$8.92B$5.56B12.6%
2023$41.62B$28.99B$8.69B$5.40B13.0%
2022$40.56B$28.68B$10.93B$8.37B20.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNY Dividend History

$2.21+8.6% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$2.421—
2025$2.211+8.6%
2024$2.041+7.0%
2023$1.901−6.9%
YearDividends per sharePaymentsChange
2026 (partial year)$2.421—
2025$2.211+8.6%
2024$2.041+7.0%
2023$1.901−6.9%
2022$2.042+7.2%
2021$1.911+8.7%
2020$1.751+0.8%
2019$1.741−6.6%
2018$1.861+18.0%
2017$1.581—

Most recent payment: $2.42 per share, ex-dividend May 4, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

SNY Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricSNYDrug Manufacturers - General medianvs median
P/E23.5324.695% below
P/S ratio2.173.1331% below
Profit margin8.09%8.09%0.0 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sanofi (SNY) is capitalised at $106.01B on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 74,846 employees.

SNY last closed at $44.24 on September 4, 2026. That is −$0.09 (−0.20%) against the previous close. The 52-week range on file runs from $40.89 to $52.68. The latest close sits 8.19% above that 52-week low.

Financial Health

In fiscal 2025, Sanofi reported revenue of $46.72B. Against the prior fiscal year total of $44.29B, that is a change of +5.49%. The same year closed with net income of $7.81B. That is +40.52% against the prior fiscal year. The reported profit margin is 8.09%. Trailing earnings per share are 1.88.

Across the 4 fiscal years on file, revenue moves from $40.56B in 2022 to $46.72B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 23.53. That is 4.7% below the Drug Manufacturers - General median of 24.69. The forward P/E on file is 8.16. The PEG ratio, which sets the P/E against expected earnings growth, reads 29.56. The price-to-sales ratio is 2.17. On price-to-sales that is 30.8% below the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

The trailing one-year price return is +3.01%. Measured over 10 years, that is +5.46% a year compounded. The reported beta is 0.28. Daily returns over the trailing 10 years annualize to a volatility of 23.48%.

Growth & Income

The trailing dividend yield is 5.46%. That is 2.8 percentage points above the Drug Manufacturers - General median yield of 2.7%. At the indicated rate that is $2.42 a share a year. The ex-dividend date on file is May 4, 2026. Dividends are recorded for 10 calendar years; 2026 shows 1 payments totalling $2.42 a share. The year before, 2025, totalled $2.21 a share.

Across the complete calendar years on file, 2019 returned +20.47% and 2020 returned +0.38%. Of the 9 complete calendar years on file, 9 finished higher. So far in 2026 the price is −3.64%.

Peer Comparison

Sanofi (SNY) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sanofi SNY $106.01B 23.5
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Sanofi trades at a P/E of 23.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Visit website →